Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elsubrutinib/ upadacitinib - AbbVie

Next Previous
Drug Profile

Elsubrutinib/ upadacitinib - AbbVie

Alternative Names: ABBV 105/ABT 494 -AbbVie; ABBV-105/upadacitinib-combination; ABBV-599

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie Germany
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 14 Nov 2024 Efficacy and adverse events data from long term extension of phase II trial in Systemic lupus erythematosus presented at the ACR Convergence 2024 (ACR-2024)
  • 12 Jun 2024 Efficacy data from the phase-II SLEek trial in Systemic lupus erythematosus presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 03 Jun 2023 Efficacy data from a phase II trial in Systemic lupus erythematosus presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top